MET signaling is implicated in cell proliferation, migration, invasion, and survival. Genomic alterations in MET can manifest in driving oncogenesis in the form of MET exon 14 skipping mutations (METex14) or other activating mutations, MET gene amplification, gene fusion and MET protein overexpression. METex14 is an independent prognostic factor associated with poorer survival rates in patients with NSCLC. Avistone is developing Vebreltinib (also referred to as PLB1001, Bozitinib) to treat NSLCLC patients with MET exon 14 skipping alternations and in other potential indications in China.

As of August 9, 2022, 113 patients were enrolled in the China study, among whom 52 patients had METex14 skipping mutations (Cohort 1). Per the blinded independent review committee (BIRC), the primary endpoint of objective response rate (ORR) was 75% (95% CI: 61.1%-86.0%), with 39 participants achieving a complete response (CR) or partial response (PR). The treatment-naïve and previously treated patients displayed an ORR of 77.1% (95% CI, 59.9%-89.6%) and 70.6% (95% CI,44.0%-89.7%), respectively. The median progression free survival (PFS) was 14.1 months (95% CI, 6.4-17.9) and the median overall survival (OS) was 20.7 months (95% CI, 16.2-NE). Most of the TRAEs were grade 1/2.

“We are proud and excited to share data for Vebreltinib at this year’s ESMO Congress which has best-in-class potential for patients with MET aberrations in NSCLC,” said Dr. Hepeng Shi, Chairman, CEO, and Founder of Avistone.

Electronic copies of the poster presented at the ESMO Congress are available upon request.

About Avistone Biotechnology Co. Ltd.

Avistone is an oncology company focused on developing innovative therapies for patients with significant unmet medical needs globally. Avistone has an extensive pipeline of targeted therapies including two clinical-stage drug candidates and several ongoing programs in the pre-clinical development stage. The Company’s lead asset is PLB1001, a small-molecule inhibitor that targets MET tyrosine kinase activity, including aberrant activity observed with METexon14 skipping (genetic) alterations in NSCLC tumors and in other solid tumors. The company’s second clinical asset is PLB1004, a potent inhibitor of EGFR tyrosine kinases (TKI), including aberrant activity observed with EGFR exon20 insertion (genetic) mutations in NSCLC tumors.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231023842513/en/